



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
06/740,750, filed 07/02/97	07/02/97	ELVETY	TT 23164-1003

001444 RM11/1205
BROWDY AND NEIMARK, P.L.L.C.
824 NINTH STREET, NW
SUITE 300
WASHINGTON DC 20001-5303

EXAMINER

ANOKHA, S., J.

ART UNIT	PAPER NUMBER
1646	22

DATE MAILED: 12/05/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Advisory Action	Application No.	Applicant(s)	
	08/853,292	TOVEY, MICHAEL GERARD	
	Examiner Janet L Andres	Art Unit 1646	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 17 November 2000 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

PERIOD FOR REPLY [check only a) or b)]

a) The period for reply expires 4 months from the mailing date of the final rejection.

b) In view of the early submission of the proposed reply (within two months as set forth in MPEP § 707.07 (f)), the period for reply expires on the mailing date of this Advisory Action, OR continues to run from the mailing date of the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

1. A Notice of Appeal was filed on _____. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37CFR 1.191(d)), to avoid dismissal of the appeal.

2. The proposed amendment(s) will be entered upon the timely submission of a Notice of Appeal and Appeal Brief with requisite fees.

3. The proposed amendment(s) will not be entered because:

(a) they raise new issues that would require further consideration and/or search. (see NOTE below);

(b) they raise the issue of new matter. (see Note below);

(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or

(d) they present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: See Continuation Sheet.

4. Applicant's reply has overcome the following rejection(s): _____.

5. Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).

6. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: _____.

7. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.

8. For purposes of Appeal, the status of the claim(s) is as follows (see attached written explanation, if any):

Claim(s) allowed: _____.

Claim(s) objected to: _____.

Claim(s) rejected: _____.

Claim(s) withdrawn from consideration: _____.


9. The proposed drawing correction filed on _____ a) has b) has not been approved by the Examiner.

10. Note the attached Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____.

11. Other:

Continuation of 3. NOTE: The amendment has not been entered because the negative limitation is a limitation on the mechanism with no corresponding method step to achieve that outcome. A positive limitation, to the effect that the dosage administered be an amount sufficient to treat a preexisting viral condition, is suggested. Further, applicant has not pointed out the basis for the limitation that administration not be by mouth in multiple or continuous doses when the condition is rhinovirus. This limitation requires substantial further consideration.

Applicant argues that the prior art teaches away from the instant doses, and teaches away from treatment of preexisting conditions. The examiner is not persuaded that the art teaches that higher doses are not beneficial; Cummins appears only to teach that they are not better than lower doses. Examination of Figure 1 of Moore et al. reveals that the higher doses did result in decreased cell counts. The examiner does agree that the prior art does not fairly teach treatment of preexisting conditions. However, the claims as written do not preclude prophylaxis.



Lorraine Spector
LORRAINE SPECTOR
PRIMARY EXAMINER